SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia
16 references·0 citing·39 second hop
Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia (2016)Health benefit assessment of pharmaceutic…Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study (2015)Developing an evidence-based …The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions (2014)The Influence of Cost‐Effecti…Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluation (2013)Structural changes in the Ger…Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation (2013)Early benefit assessment (EBA…Decision making by NICE: examining the influences of evidence, process and context (2013)Decision making by NICE: exam…Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions (2012)Relative Effectiveness Assess…Commonalities and differences in HTA outcomes: A comparative analysis of five countries and implications for coverage decisions (2012)Commonalities and differences…A systematic review of coverage decision-making on health technologies—Evidence from the real world (2012)A systematic review of covera…Health Technology Funding Decision-Making Processes Around the World (2011)Health Technology Funding Dec…Availability of and Access to Orphan Drugs (2010)Availability of and Access to…Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions (2009)Using Effectiveness and Cost-…Comparative Effectiveness Research and Evidence‐Based Health Policy: Experience from Four Countries (2009)Comparative Effectiveness Res…Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared (2005)Providing guidance to the NHS…Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle (2004)Inclusion of cost effectivene…Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis (2004)Does NICE have a cost‐effecti…A Coefficient of Agreement for Nominal Scales (1960)A Coefficient of Agreement fo…Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries (2003)Assessing the economic challenges posed by orphan drugs (2007)Economics of New Oncology Drug Development (2007)The availability and affordability of orphan drugs for rare diseases in China (2016)Patient Access to Medicines for Rare Diseases in European Countries (2018)Hedonic Prices and Implicit Markets: Product Differentiation in Pure Competition (1974)National Institute for Clinical Excellence and its value judgments (2004)The NICE Cost-Effectiveness Threshold (2008)CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS? (2014)Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness (2015)Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L (2018)The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies (1999)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? (2009)Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)Health Economic Guidelines—Similarities, Differences and Some Implications (2001)Theory versuspractice: a review of ?willingness-to-pay? in health and health care (2001)Measuring Preferences for Cost-Utility Analysis (2007)Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions (2012)Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC—Does the Presence of an Explicit Threshold Affect the ICER Proposed? (2018)WORLD HEALTH ORGANISATION (1957)Key principles for the improved conduct of health technology assessments for resource allocation decisions (2008)Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland (2016)Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries (2016)The role of economic evaluation in the pricing and reimbursement of medicines (1997)The Link Between Gross Profitability And Pharmaceutical R&D Spending (2001)Examining the link between price regulation and pharmaceutical R&D investment (2004)HEALTH TECHNOLOGY ASSESSMENT, VALUE-BASED DECISION MAKING, AND INNOVATION (2013)Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers (2010)Attributes and weights in health care priority setting: A systematic review of what counts and to what extent (2015)Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries (2017)De innovatione: The concept of innovation for medical technologies and its implications for healthcare policy-making (2015)A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment? (2017)The Measurement of Observer Agreement for Categorical Data (1977)Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial Reliability and Validity Data (1997)Interrater reliability: the kappa statistic (2012)Role of patient and public participation in health technology assessment and coverage decisions (2011)Social values in health priority setting: a conceptual framework (2012)Generating comparative evidence on new drugs and devices after approval (2020)
this work references cited by second hop

References

  • 1960A Coefficient of Agreement for Nominal Scales42,335 cited
  • 2004Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis710 cited
  • 2009Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions343 cited
  • 2014The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions232 cited
  • 2004Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle194 cited
  • 2009Comparative Effectiveness Research and Evidence‐Based Health Policy: Experience from Four Countries160 cited
  • 2013Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluation102 cited
  • 2012Commonalities and differences in HTA outcomes: A comparative analysis of five countries and implications for coverage decisions93 cited
  • 2013Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation90 cited
  • 2010Availability of and Access to Orphan Drugs87 cited
  • 2011Health Technology Funding Decision-Making Processes Around the World84 cited
  • 2012Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions64 cited
  • 2015Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study61 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

  • 2013Decision making by NICE: examining the influences of evidence, process and context58 cited
  • 2012A systematic review of coverage decision-making on health technologies—Evidence from the real world56 cited
  • 2005Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared54 cited
  • Cited by

    No citing works inside the corpus for this window.